HOME
Leading the way to a cure

Scientific Advisory Board

Mary K. (Peggy) Crow, M.D. (Chair)

Mary K. Crow, M.D.  - Scientific Advisory Board Chair

Mary K. Crow, M.D., is the Benjamin M. Rosen Professor and Senior Scientist at Hospital for Special Surgery in New York and Professor of Medicine and Immunology at Weill Medical College of Cornell University. At Hospital for Special Surgery, Dr. Crow is Director of Rheumatology Research and Associate Chief of Rheumatology. In addition, she serves as Director of the Autoimmunity and Inflammation Research Program and as Co-Director of the Mary Kirkland Center for Lupus Research.

Dr. Crow earned an M.D. from Cornell University Medical College and completed an internship and internal medicine residency at New York Hospital in Manhattan. Her rheumatology clinical fellowship training was performed at Hospital for Special Surgery. She also served as a post-doctoral research fellow at Rockefeller University, where she was mentored by Dr. Henry Kunkel, a renowned immunologist who made significant contributions to the understanding of the mechanisms responsible for autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Dr. Crow served as President of the American College of Rheumatology (2005-2006) and is very active in the rheumatology research community. Her own research has focused on the induction and regulation of human autoimmunity. She was among the first to characterize the functional properties of human dendritic cells and has studied self-reactive T cells in the prototype systemic autoimmune diseases, systemic lupus erythematous and rheumatoid arthritis. She continues to investigate the underlying triggers of autoimmune disease and the cellular and cytokine mediators of uncontrolled immune system activation in those disorders. She has published more than seventy scientific papers and has received research grant support from the NIH, the Arthritis Foundation, the Alliance for Lupus Research, the Lupus Research Institute, and the Mary Kirkland Center for Lupus Research. She was named an “Arthritis Hero” by the Arthritis Foundation in 2001. 

Dennis A. Carson, M.D.

Dennis A. Carson, M.D.

Dennis A. Carson, M.D. is the Director, of the Moores Cancer Center, University of California San Diego (UCSD) School of Medicine. Carson earned his medical degree at Columbia University, completed his residency at UCSD, and received post-doctoral training at the Salk Institute, the National Institutes of Health and UCSD. He has published over 470 scientific papers, is an inventor on more than 70 issued U.S. patents, and has founded six biotechnology companies working in the oncology field. He is a member the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Carson is perhaps best known for developing 2-chlorodeoxyadenosine, or 2-CdA, for the treatment of hairy cell leukemia. This drug is the treatment of choice for this disease and has resulted in long term, complete remissions in about 75 percent of patients. He is convinced that novel partnerships between the public and private sectors are necessary to develop the next generation of anticancer treatments. As Cancer Center Director his priorities have been to develop strong, formalized relationships with the biotechnology and pharmaceutical communities to speed the translation of basic science discoveries, while maintaining academic freedom and economic incentives.

Robert L. Coffman, Ph.D.

Dennis A. Carson, M.D.

Robert L. Coffman, Ph.D. is the Vice President and Chief Scientific Officer of Dynavax Technologies in Berkeley, CA. Prior to joining Dynavax in 2000, Dr. Coffman was a founding member of the Scientific Staff of the DNAX Research Institute in Palo Alto, CA. Dr. Coffman has authored over 200 scientific publications and is a member of the National Academy of Sciences and the American Academy of Microbiology. He has devoted over 25 years to discovery of the pathways of immune regulation by T cells and cytokines. Dr. Coffman demonstrated that Interleukin-4 and Interferon- were the principal cytokines regulating IgE production in allergic responses. In 1986, with colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated subsequently that all of the major features of allergic responses were coordinately regulated by the Th2 subset of T cells. Dr. Coffman demonstrated that Interleukin-4 mediated class switching to IgE by controlling rearrangement of immunoglobulin genes and discovered the parallel mechanism for the regulation of IgA responses by Transforming Growth Factor-B.
Dr .Coffman has defined mechanisms of T cell regulation in asthma and infectious and parasitic diseases and demonstrated of the central role regulatory CD4+ T cells in preventing inflammatory bowel disease. In his current position at Dynavax Technologies, Dr. Coffman is developing agonists and antagonists for Toll-like receptors, key recognition receptors in innate immunity. These compounds show promise as novel therapeutic agents for the treatment of allergic, infectious and autoimmune diseases.

Anthony Coyle, Ph.D.

Anthony Coyle, Ph.D.

Anthony “Tony” Coyle is Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI). CTI was established in August 2010 as a new model to drive innovation in BioTherapeutics R & D. Tony is responsible for the CTI sites, which currently include CTI – New York City, CTI- Boston and CTI-California. Tony is supported by his leadership team, which will include the site heads of each CTI, his operations team, project management, clinical and Precision Medicine heads.

Tony brings an extensive knowledge of the full development process to Pfizer. As a former Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca, Tony has succeeded in advancing a biologic portfolio from discovery to Phase Two in the areas of Lupus, Asthma and COPD.

Prior to Medimmune, Tony was Director of Research and Biology at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes as well as for late stage lead optimization and delivery of both small molecule and biologic development candidates.

Tony has been Associate Professor in the Department of Pathology and Experimental Therapeutics at McMaster University in Ontario since 1992, and has authored more than 180 manuscripts. He holds a B.Sc. Honours and a Ph.D. from Kings College, University of London.

Richard Furie, M.D.

Richard Furie, M.D.

Dr. Richard Furie, Chief of the Division of Rheumatology and Allergy-Clinical Immunology at the North Shore LIJ Health System, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and is a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board. Dr. Furie has served on many committees of the American College of Rheumatology, and has recently been appointed to the College’s Board of Directors

Bevra Hahn

Bevra Hahn

Bevra H. Hahn is Professor of Medicine, Vice-Chair of the Department of Medicine, and Chief of Rheumatology at the David Geffen School of Medicine, University of California Los Angeles, where she has been since 1983. A summa-cum-laude graduate of Ohio State University, Dr. Hahn received her medical degree from Johns Hopkins.She has been elected to Phi Beta Kappa, Alpha Omega Alpha, the American Society of Clinical Investigators, the Association of American Physicians and the Johns Hopkins Society of Scholars. She did an internship and residency in medicine in St. Louis at Barnes Hospital, Washington University. She is past-president of the American College of Rheumatology (ACR) and is currently a Master. She serves as the Chair of the NIH/NIAID Immune Tolerance Network Data and Safety Monitoring Board, and member of the Council of Councils, which is advisory to the Director of the NIH. Among her awards are the Dunlop-Dottridge Award of the Canadian Rheumatism Association for research in rheumatology, the Joseph Bunim Medal and prize of the American College of Rheumatology, the Holley Research prize in Rheumatology, the Southern California Arthritis Foundation's Klinenberg Medal for Arthritis Research, the Carol-Nachman International Award for Rheumatology Research, the first Evelyn V Hess Award of the Lupus Foundation of America for research in SLE, the 2007 ACR/REF Award of Distinction for Academic Mentoring, and the 2009 ACR Gold Medal. Dr. Hahn has authored more than 130 peer-reviewed research papers and over 40 book chapters or reviews as well as serving as co-editor of an influential textbook Dubois’ Lupus Erythematosus. She has served on the editorial boards of the Journal of Clinical Investigation and the Annals of Internal Medicine>. Her current research at the Laboratory for Lupus Research at UCLA includes investigations in immune tolerance, regulatory CD4+ and CD8+ T cells, genetics, accelerated atherosclerosis and treatment of systemic lupus. The laboratory is funded by grants from the National Institutes of Health, the Arthritis Foundation (Southern California Chapter), the American College of Rheumatology/Research Education Foundation, a Lupus Clinical Trials Center award, Rheuminations and private donors including Jeanne Rappaport.

Peter E. Lipsky, M.D.

Richard Flavell, Ph.D.

Dr. Peter E. Lipsky received his medical degree from the New York University School of Medicine and spent much of his career at the University of Texas Medical Center, initially as Instructor in Internal Medicine and later as Professor of Internal Medicine and Microbiology.  Later appointments at the University of Texas Medical Center (1984-1999) included Director of the Harold C Simmons Arthritis Research Center, Co-Director of the Immunology Graduate Program at the Southwestern Graduate School of Biomedical Sciences, and Director of the Rheumatic Disease Division of the Department of Internal Medicine. Dr Lipsky was named the Harold C Simmons Professor in Arthritis Research in 1995, a position he held for 5 years.

Dr Lipsky's major research interests are B-cell biology, both in normal and autoimmune disease settings, and the generation of the immunoglobulin repertoire, and has authored over 500 articles. He serves on numerous journal editorial boards, and is the Co-Editor of Arthritis Research and Therapy and the Editor in Chief for Nature Clinical Practice Rheumatology. He has been awarded numerous prizes, including the Carol Nachman Prize in 2001, the Lee C. Howley Prize for Arthritis Research in 2002, the American College of Rheumatology's Distinguished Investigator Award in 2002, and the Japan Rheumatology Prize 2006.

Mike McCune, M.D., Ph.D.

Mike McCune, M.D., Ph.D

Research in the McCune Lab has focused on the definition of pathogenic mechanisms of viral diseases, particularly HIV disease. This focus has spanned a range of fields, from understanding critical structural determinants of infectivity, to devising a small animal model (the SCID-hu Thy/Liv mouse) to study HIV pathogenesis and to prioritize antiretroviral compounds against HIV, to studying mechanisms of T cell depletion and repletion in vivo. Throughout this body of work, he has engaged in hypothesis-driven, patient-oriented research that has involved collaborative teams of basic scientists, translational researchers, and clinicians. Most recently, he has devoted all of his attention to understanding the correlates of protective immunity against HIV, with the specific intent to work with others to eradicate HIV. This change of focus has now been materialized at UCSF by the creation of the Division of Experimental Medicine, of which Dr. McCune is the Chief. From 2005-2008, he served as the PI and Director of the Clinical and Translational Science Institute at UCSF, an organization whose mission is to enhance and to facilitate the process by which better therapies can be brought from the lab bench to the community more quickly. In this capacity, he also served as the Senior Associate Dean of Clinical and Translational Research in the Schools of Dentistry, Medicine, Nursing, and Pharmacy at UCSF.

In the Division of Experimental Medicine, he has established a multidisciplinary, collaborative environment for the analysis of the human immunology of chronic infectious diseases of medical importance, including those caused by HIV, TB, malaria, and helminthic worms. The underlying hypothesis of the Division is that each of these agents has established patterns of interaction with the host which, in most cases, do not lead to overt disease; that these patterns are likely to embrace protective immune responses with mechanistic overlaps; and that elucidation of such common patterns of successful host-pathogen interaction may inform the development of interventions (e.g., vaccines and medicines) to successfully fight HIV.

Jane Salmon, M.D.

Jane Salmon, M.D.

Dr. Jane Salmon is Professor of Medicine and Professor of Obstetrics and Gynecology at Weill Cornell Medical College and the Collette Kean Research Professor at Hospital for Special Surgery.

Dr. Salmon graduated magna cum laude from New York University and earned a medical degree in 1978 from the College of Physicians and Surgeons of Columbia University, where she was the first woman enrolled in their Medical Scientist Training Program. She completed training in internal medicine at The New York Hospital and in rheumatology at Hospital for Special Surgery, and has been an HSS faculty member since 1983. Dr. Salmon has served on the Board of Directors of the American College of Rheumatology and as Councilor of the Clinical Immunology Society. She has served on the NIH Advisory Boards for the North American Rheumatoid Arthritis Consortium and the Lupus Multiplex Registry and was co-editor of Arthritis and Rheumatism. At Hospital for Special Surgery, she is a co-Director of the Mary Kirkland Center for Lupus Research, Director of the SLE APS Center of Excellence, Director of the FOCIS Center of Excellence, and Director of the Lupus Registry and Repository.

Dr. Salmon’s research has focused on elucidating mechanisms of tissue injury in lupus and other autoimmune diseases. Her basic and clinical studies have expanded our understanding of pregnancy loss and organ damage in SLE and the determinants of disease outcome in lupus patients with nephritis, pregnancy, and cardiovascular disease.

George Tsokos, M.D.

George Tsokos, M.D.

Dr. Tsokos received his Medical Degree and a Doctorate in Sciences from the University of Athens. He trained in Internal Medicine at the University of Athens and Georgetown University/VA Medical Center in Washington DC and completed Immunology and Rheumatology Fellowships at the National Institutes of Health. Between 1987 and 2007 he was a member of the Uniformed Services/Walter Reed community where served in various positions including Vice Chair for Research in the Department of Medicine and Chief of the Department of Cell Injury. In 2007 he joined the Beth Israel Medical Center as Chief of Rheumatology and Harvard Medical School as Professor of Medicine.

He has served various leadership positions including President of the Clinical Immunology Society and as member or chair of multiple federal study sections and editorial boards of scientific journals. He has served (or serves) as Consulting Editor of the Journal of Clinical Investigation, Editor of Autoimmunity, Academic Editor of PLOS One and Editor-in-Chief of Clinical Immunology. He has been elected to the Association of American Physicians, Fellow of the American Association for the Advancement of Sciences and Master of the American College of Physicians.

Dr. Tsokos’ research focuses on the cellular and molecular pathogenesis of systemic lupus erythematosus (SLE). His laboratory has opened and led the field of molecular abnormalities on immune cells in patients with SLE. He has identified several molecular abnormalities, including aberrant expression of CD3 zeta chain, cAMP response element modulator, calcium-calmodulin kinase IV and protein phosphatase 2A and demonstrated that when their expression is corrected in cells obtained from patients with SLE with either gene transfer or small molecule drugs the effector cell function returns to normal levels. More recently he has constructed a series of novel mice to demonstrate in vivo the importance of the molecules expressed aberrantly in SLE T cells in the expression of autoimmunity and organ damage.

Dr. Tsokos has trained over 100 colleagues many of whom hold senior leadership positions and run independent laboratories and has published more than 450 articles. His research is funded by NIH and DoD grants.

2011 ALR SAB Members

2010 ALR SAB Members 

 


1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software